By a News Reporter-Staff News Editor at Biotech Week -- New research on Drugs and Therapies is the subject of a report. According to news reporting out of Changsha, People's Republic of China, by NewsRx editors, research stated, "Microvasculature and microenvironment play important roles in proliferation, invasion, metastasis and prognosis in non-small cell lung cancer (NSCLC), which might be altered by many anti-angiogenic drugs. Epigallocatechin-3-gallate (EGCG), a natural anti-angiogenesis agent refined from green tea, was defined to have multiple effects on angiogenesis factors, such as endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and angiopoietins (ANGs)."
Our news journalists obtained a quote from the research from Central South University, "Hypothesizing that EGCG might regulate microvasculature and microenvironment in NSCLC, the effects of EGCG on microvessel density (MVD), expression of Ang-1 and Ang-2, interstitial fluid pressure (IFP), tumor hypoxia, and chemotherapy sensitivity were examined. EGCG treatment of A549 cells in mice bearing xenografts in vivo led to a significant decrease of MVD detected by CD31, and of Ang-2 expression detected by quantum dots double-label immunofluorescence assessment, while Ang-1 decreased with no significance. Decreased IFP was measured by the Wink-in-needle method, while hypoxia was assessed by polarographic electrode and pimonidazole (PIMO) immunohistochemistry. Assuming that these changes would increase response to chemotherapy, tumor growth studies were p[erformed in nude mice with xenografts, which were then treated with EGCG and the chemotherapeutic agent cisplatin. EGCG therapy combined with cisplatin led to synergistic inhibition of tumor growth, compared with administration of each treatment separately (p
According to the news editors, the research concluded: "These studies established a new mechanism for using EGCG as an adjuvant chemotherapy agent through modifying microvasculature and microenvironment."
For more information on this research see: Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2. Chinese Journal of Natural Medicines, 2013;11(3):245-53. (Elsevier - www.elsevier.com; Chinese Journal of Natural Medicines - www.elsevier.com/wps/product/cws_home/719667)
Our news journalists report that additional information may be obtained by contacting P.B. Deng, Dept. of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, People's Taiwan. Additional authors for this research include C.P. Hu, Z. Xiong, H.P. Yang and Y.Y Li (see also Drugs and Therapies).
Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Changsha, Cisplatin, Treatment, Alkylating Agents, Drugs and Therapies, Adjuvant Chemotherapy, Combined Modality Therapy, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC